Prostaglandin E1
|
|
| Systematic (IUPAC) name |
| 7-[(1R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoic acid |
| Clinical data |
| MedlinePlus |
a695022 |
| Pregnancy cat. |
C (US) |
| Legal status |
? |
| Identifiers |
| CAS number |
745-65-3 Y |
| ATC code |
C01EA01 G04BE01 |
| PubChem |
CID 149351 |
| IUPHAR ligand |
1882 |
| DrugBank |
DB00770 |
| ChEMBL |
CHEMBL495 N |
| Chemical data |
| Formula |
C20H34O5 |
| Mol. mass |
354.481 g/mol |
N (what is this?) (verify)
|
Prostaglandin E1 (PGE1), known pharmaceutically as alprostadil,[1] is a prostaglandin. It is a drug used in the treatment of erectile dysfunction[2] and has vasodilatory properties.
|
Contents
- 1 Medical uses
- 1.1 Patent ductus arteriosus
- 1.2 Sexual dysfunction
- 1.3 Critical limb ischemia
- 2 Adverse effects
- 3 Pharmacokinetics
- 4 References
|
Medical uses
Patent ductus arteriosus
Alprostadil is also used in maintaining a patent ductus arteriosus in newborns. This is primarily useful when there is threat of premature closure of the ductus arteriosus in an infant with ductal-dependent congenital heart disease, including cyanotic lesions (e.g., pulmonary atresia/stenosis, tricuspid atresia/stenosis, transposition of the great arteries) and acyanotic lesions (e.g., coarctation of the aorta, hypoplastic left heart syndrome, critical aortic stenosis, interrupted aortic arch).
Sexual dysfunction
Alprostadil is sold in the United States as urethral suppositories and in injectable form. The suppositories are sold under the brand name MUSE.[3] The injectable forms are Edex[4] and Caverject.[5] Muse delivers alprostadil as a penile suppository, inserted into the urethra, at least ten minutes before the erection will be needed. Caverject and Edex are similarly fast-acting, but instead are injected by syringe directly into the corpus cavernosum of the penis.
Apricus Biosciences is developing proprietary drugs; Vitaros for men with erectile dysfunction, Femprox for female sexual arousal disorder and RayVa for Raynaud’s phenomenon. Two Phase III studies have been completed for Vitaros, and approval has been granted in Canada. Apricus Biosciences is seeking regulatory approval in Europe, South America, and other territories. Apricus Biosciences sold the rights for Vitaros in the US to Warner Chilcott.[6]
Alprostadil is also available as a generic. The major cost is that it must be mixed by a compounding pharmacy and supplies of alprostadil may be difficult to obtain. There are different formulations, including Bimix and Trimix, which may include papaverine and/or phentolamine. A typical mix might be 30 mg of papaverine, 2 mg of phentolamine, and 20 mcg alprostadil. As a generic, it is much less expensive than the pre-packaged injectables. It is premixed and must be kept refrigerated and the user must load a syringe with the quantity needed.
Critical limb ischemia
Alprostadil is also used for critical limb ischemia. It increases blood flow by peripheral vasodilation within 5 minutes and induces angiogenesis. It is most effective when the ankle pressure is at least 30 mmHg and at least one tibial artery is patent.
Adverse effects
- Apnea
- Flushing
- bradycardia
- hypotension
- tachycardia
- cardiac arrest
- edema
- CHF
- hyperemia
- second-degree heart block
- shock
- spasm of right ventricle infundibulum
- supraventricular tachycardia
- ventricular fibrillation
- Fever
- seizures
- Cerebral bleeding
- Diarrhea
- Urethral pain
- urethral burning
- urethral bleeding/spotting
- testicular pain ( Muse only)
- Hematologic
- DIC
- bleeding
- Cortical proliferation of long bones
- sepsis
- penile pain
- prolonged erection
- penile fibrosis
- injection-site hematoma
- penis disorder
- injection-site ecchymosis ( Caverject only)
- back pain
- pain
- pelvic pain
- accidental injury ( Muse only)
Pharmacokinetics
|
This section is empty. You can help by adding to it. (March 2013) |
References
- ^ Cawello W, Leonhardt A, Schweer H, Seyberth HW, Bonn R, Lomeli AL (September 1995). "Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion". British Journal of Clinical Pharmacology 40 (3): 273–6. PMC 1365109. PMID 8527291. //www.ncbi.nlm.nih.gov/pmc/articles/PMC1365109/.
- ^ Harding LM, Adeniyi A, Everson R, Barker S, Ralph DJ, Baranowski AP (December 2002). "Comparison of a needle-free high-pressure injection system with needle-tipped injection of intracavernosal alprostadil for erectile dysfunction". International Journal of Impotence Research 14 (6): 498–501. doi:10.1038/sj.ijir.3900916. PMID 12494285.
- ^ "Muse Suppository - Facts and Comparisons". Drugs.com. http://www.drugs.com/cdi/muse-suppository.html. Retrieved 4 January 2013.
- ^ Edex - Facts and Comparisons Drugs.com
- ^ Caverject - Facts and Comparisons Drugs.com
- ^ Fain Hughes (2007-10-29). "NEXM: Dutton Sees Strong Speculative Buy and 12-Month Price Double". http://www.tradingmarkets.com/.site/news/Stock%20News/722371/. Retrieved 2007-11-01.
|
Drugs for erectile dysfunction (G04BE) and premature ejaculation
|
|
| For erectile dysfunction |
|
Prostaglandins (E)
|
|
|
|
PDE5 inhibitors
|
- Avanafil
- Sildenafil
- Tadalafil
- Udenafil
- Vardenafil
|
|
|
Alpha blockers
|
- Moxisylyte
- Phentolamine
- Yohimbine
|
|
|
Dopamine D4 receptor agonists
|
|
|
|
Others
|
|
|
|
| For premature ejaculation |
|
SSRIs
|
|
|
|
Oxytocin receptor antagonists
|
|
|
|
|
|
|
noco/cong/tumr, sysi/epon
|
|
|
|
|
|
Autacoids, unsaturated fatty acids: Eicosanoids
|
|
| Precursor |
|
|
| Prostanoids |
Prostaglandins (PG) and
analogues |
| Precursor |
|
|
| Active |
| D/J |
|
|
| E/F |
- E2 (Dinoprostone): Enprostil
- Sulprostone
- E1 (Alprostadil): Misoprostol
- Gemeprost
- F2α (Dinoprost): Bimatoprost
- Carboprost
- Latanoprost
- Tafluprost
- Travoprost
- Unoprostone
|
|
| I |
- I2 (Prostacyclin/Epoprostenol): Beraprost
- Iloprost
- Treprostinil
|
|
|
|
| Thromboxanes (TX) |
|
|
|
| Leukotrienes (LT) |
| Precursor |
- Arachidonic acid 5-hydroperoxide
|
|
| Initial |
|
|
| SRS-A |
|
|
|
| Nonclassic |
- Lipoxins (A4, B4)
- Virodhamine
|
|
| By function |
- vasoconstriction
- vasodilation
- platelets: induce
- inhibit
- leukocytes: induce
- inhibit
- labor stimulation:
- PGE2 (Dinoprostone)
- PGF2α (Dinoprost)
|
|
|
|
mt, k, c/g/r/p/y/i, f/h/s/l/o/e, a/u, n, m
|
k, cgrp/y/i, f/h/s/l/o/e, au, n, m, epon
|
m (A16/C10), i (k, c/g/r/p/y/i, f/h/s/o/e, a/u, n, m)
|
|
- biochemical families: carbohydrates
- alcohols
- glycoproteins
- glycosides
- lipids
- eicosanoids
- fatty acids / intermediates
- phospholipids
- sphingolipids
- steroids
- nucleic acids
- constituents / intermediates
- proteins
- amino acids / intermediates
- tetrapyrroles / intermediates
|
|